Heart help for cancer survivors: exercise and diet study launches
NCT ID NCT00633633
First seen Jun 25, 2026 · Last updated Jul 31, 2026 · Updated 2 times
Summary
This study looks at whether exercise training and dietary counseling can help cancer survivors who have heart failure. About 85 participants will either receive usual care or join a program with exercise three times a week and low-salt diet guidance. The goal is to see if this lifestyle approach is practical and can improve how patients feel.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Exercise training and dietary counseling
- What this could lead to
- If successful, this could show that a structured exercise and diet program helps cancer survivors manage heart failure symptoms and improve daily life.
- What could go wrong
- This is a small early-stage study focused on feasibility, not on proving medical benefit. Results may not apply to all survivors, and lifestyle changes can be hard to maintain.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 85 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Feb 2008
- Expected to finish
-
May 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. diagnosis of NYHA I, II or III heart failure (as identified by any of the following physical findings of heart failure (jugular venous distension, crackles, edema, S3); pulmonary edema on chest x-ray; BNP \> 100 pg/ml; or at least two of the following symptoms: paroxysmal nocturnal dyspnea, shortness of breath, swelling, fatigue; 2. previous chemotherapy that contributed to the development of heart failure (i.e., heart failure develops or worsens after receiving chemotherapy, with no other obvious explanation); 3. oriented to person, place, and time; 4. living in the Houston area (Harris county or a contiguous county), or planning to stay in the area for at least the next 16 weeks. 5. 18 years of age or older. 6. diagnosis of cancer 7. have completed treatment, or are on long-term adjuvant or maintenance chemotherapy only Exclusion Criteria: 1. remain in NYHA class IV heart failure despite therapy; 2. have health problems or current treatments that would make exercise unsafe, as determined by the cardiologist; 3. cannot provide informed consent;
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The University of Texas Health Science Center at San Antonio
San Antonio, Texas, 78249, United States
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can colorectal surgery patients go home in two days?
- Can a personal navigator help young cancer patients through treatment?
- Can a smartwatch predict which cancer patients return to hospital?
- Which SGLT2 inhibitor wins? trial pits empagliflozin against dapagliflozin
- Two-Drug combo aims to stall advanced breast cancer
- Blood thinner flush could boost tumor biopsy success